title: C-5 propyne-modified oligonucleotides penetrate the epidermis in psoriatic and not normal human skin after topical application.
abstract: We have previously shown that antisense oligonucleotides effectively reduced insulin-like growth factor I receptor expression in human psoriatic skin grafted on to nude mice when injected intradermally. We therefore investigated the penetration of C-5 propyne modified antisense oligonucleotides into human normal and psoriatic skin after topical administration. Oligonucleotide (37.5 microg; 250 microM) was applied in aqueous solution or 5% methylcellulose gel for 24 h, prior to live confocal microscopy and fluorescence microscopy of fixed sections. We found that oligonucleotide could penetrate through the stratum corneum of psoriatic but not normal human skin over large regions of the epidermis. The oligonucleotide was localized to the nucleus of large parakeratotic cells in the psoriatic skin as well as smaller basal and suprabasal keratinocytes. In normal human skin, oligonucleotide was confined to the stratum corneum, with little or no oligonucleotide apparent in the viable epidermis. Electrophoresis of oligonucleotide recovered from treated psoriatic and normal skin revealed that the oligonucleotide remained intact over the 24 h period. In summary, we found that C-5 propyne modified antisense oligonucleotides could reach the target cells (in this case basal keratinocytes) after topical administration to psoriatic but not normal skin.
authors.affiliation: Department of Pharmaceutical Biology & Pharmacology, Victorian College of Pharmacy, Monash University, Parkville, Victoria, Australia. paul.white@vcp.monash.edu.au
authors.forename: Paul J
authors.initials: PJ
authors.lastname: White
authors.forename: Andrew C
authors.initials: AC
authors.lastname: Gray
authors.forename: Rhys D
authors.initials: RD
authors.lastname: Fogarty
authors.forename: Rodney D
authors.initials: RD
authors.lastname: Sinclair
authors.forename: Susan P
authors.initials: SP
authors.lastname: Thumiger
authors.forename: George A
authors.initials: GA
authors.lastname: Werther
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Wraight
mesh_terms: D000287:Administration, Topical; D000480:Alkynes; D004817:Epidermis / Q000378:metabolism*; D016650:Fluorescein-5-isothiocyanate / Q000493:pharmacokinetics; D005456:Fluorescent Dyes / Q000493:pharmacokinetics; D005782:Gels; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D066298:In Vitro Techniques; D015603:Keratinocytes / Q000378:metabolism; D008747:Methylcellulose; D008856:Microscopy, Fluorescence; D016376:Oligonucleotides, Antisense / Q000493:pharmacokinetics*; D011565:Psoriasis / Q000378:metabolism* / Q000628:therapy
chemical_list: D000480:Alkynes; D005456:Fluorescent Dyes; D005782:Gels; D016376:Oligonucleotides, Antisense; C022030:methylacetylene; D008747:Methylcellulose; D016650:Fluorescein-5-isothiocyanate